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Abstract 
Background 
DNA methylation levels change with age. Recent studies have identified biomarkers of 
chronological age based on DNA methylation levels. It is not yet known whether DNA 
methylation age captures aspects of biological age. 
Results 
Here we test whether differences between people’s chronological ages and estimated ages, 
DNA methylation age, predict all-cause mortality in later life. The difference between DNA 
methylation age and chronological age, (∆age), was calculated in four longitudinal cohorts of 
older people. Meta-analysis of proportional hazards models from the four cohorts was used to 
determine the association between ∆age and mortality. A 5-year higher ∆age is associated with 
a 21% higher mortality risk, adjusting for age and sex. After further adjustments for 
childhood IQ, education, social class, hypertension, diabetes, cardiovascular disease, and 
APOE e4 status, there is a 16% increased mortality risk for those with a 5-year higher ∆age. A 
pedigree-based heritability analysis of ∆age was conducted in a separate cohort. The 
heritability of ∆age was 0.43. 
Conclusions 
DNA methylation-derived measures of accelerated ageing are heritable traits that predict 
mortality independently of health status, lifestyle factors, and known genetic factors. 
Background 
DNA sequence variants and epigenetic marks that are associated with changes in gene 
expression contribute to interindividual variation in complex phenotypes. Epigenetic 
mechanisms such as DNA methylation, characterised by the addition of a methyl group to a 
cytosine nucleotide primarily at cytosine-phosphate-guanine (CpG) sites, play essential roles 
during development, acting through the regulation of gene expression [1]. Unlike genomic 
variants, such as single nucleotide polymorphisms (SNPs), levels of DNA methylation vary 
across the life course [2-6]. DNA methylation levels are influenced by lifestyle and 
environmental factors [7], as well as by genetic variation [8,9]. 
Age-related changes in DNA methylation are also well documented, and two recent studies 
used methylation measures from multiple CpG sites across the genome to predict 
chronological age in humans [10,11]. Hannum et al. created an age predictor based on a 
single cohort in which DNA methylation was measured in whole blood [10]. Horvath 
developed an age predictor using DNA methylation data from multiple studies (including the 
Hannum dataset) and multiple tissues [11]. In both studies, the difference between 
methylation-predicted age and chronological age (i.e., ∆age) was put forth as an index of 
disproportionate ‘biological’ ageing and was hypothesized to be associated with risk for age-
related diseases and mortality [10,11]. Weidner et al. [12] proposed an age predictor based on 
three CpGs taken from a methylation array with fewer total CpG sites than the Hannum and 
Horvath models (27 k probes versus 450 k probes). To date, however, no study has tested 
whether DNA methylation-based ∆age or other genome-wide DNA methylation biomarkers 
are significant predictors of all-cause mortality. 
Here, we tested the association of two DNA methylation measures of ∆age (using the Hannum 
and Horvath predictors) with all-cause mortality in four cohorts: the Lothian Birth Cohorts of 
1921, and 1936 [13-15], the Framingham Heart Study [16,17], and the Normative Aging 
Study [18,19]. In addition, we estimated the heritability of ∆age using the Brisbane Systems 
Genetics Study (BSGS) [20]. 
Results 
The association between ∆age (DNA methylation-predicted age minus chronological age) and 
mortality was examined in four cohorts: Lothian Birth Cohort 1921, LBC1921, (N = 446, 
ndeaths = 292), Lothian Birth Cohort 1936, LBC1936, (N = 920, ndeaths = 106), the Framingham 
Heart Study, FHS, (N = 2,635, ndeaths = 238), and the Normative Aging Study, NAS, (N = 
657, ndeaths = 226). The mean ages of the cohorts were 79.1 (SD 0.6), 69.5 (SD 0.8), 66.3 (SD 
8.9), and 72.9 (SD 6.9) years, respectively. The Hannum predicted values were higher than 
the participants’ chronological ages by a mean of 2 to 6 years (SDs ~5 years) across the four 
cohorts. The Horvath predicted values were lower than the chronological ages in LBC1921 
and LBC1936 participants by 4 to 5 years (SD ~6 years) but very similar to chronological age 
in the FHS (−0.60 years; SD 5.2) and the NAS (0.6 years; SD 5.8). A third predictor, based 
on the Weidner predictor was also examined, although it had a low correlation with 
chronological age (LBC1921: Pearson R = 0.02; LBC1936: Pearson R = −0.03; FHS: Pearson 
R = 0.25; NAS: Pearson R = 0.43) and very large absolute median differences (LBC1921: 
29.9 years, LBC1936: 19.8 years, FHS: 12.6 years, NAS: 18.4 years) so was not examined 
further. A full description of the cohorts is provided in Table 1 and Additional file 1. 
Combining information from these studies, the correlation between chronological age and 
predicted age was 0.83 for the Hannum measure and 0.75 for the Horvath measure (Figure 1). 
The correlation between the Hannum and Horvath predictors was 0.77. 
  
Table 1 Summary details of the four analysis cohorts 
 LBC1921 LBC1936 FHS NAS 
N 446 920 2635 657 
n deaths 292 106 238 226 
Time to death (years) 7.2 (3.5) 4.4 (2.2) 6.0 (1.2) 10.5 (3.3) 
Age (years) 79.1 (0.6) 69.5 (0.8) 66.3 (8.9) 72.9 (6.9) 
Sex (male) 176 (40%) 465 (51%) 1200 (46%) 657 (100%) 
Hannum methylation age (years) 85.0 (5.6) 75.8 (5.0) 68.2 (8.7) 77.6 (6.7) 
Hannum ∆age (years) 5.9 (5.6) 6.2 (5.1) 1.9 (4.8) 4.6 (4.8) 
Hannum median error (years) 5.5 6.4 1.9 4.6 
Horvath methylation age (years) 73.7 (6.2) 66.0 (5.8) 65.7 (8.3) 73.5 (7.4) 
Horvath ∆age (years) −5.4 (6.3) −3.6 (5.8) −0.6 (5.2) 0.6 (5.8) 
Horvath median error (years) 6.0 4.7 0.69 3.4 
Tissue sample whole blood whole blood whole blood buffy coat 
Methylation array Illumina 450 k Illumina 450 k Illumina 450 k Illumina 450 k 
LBC: Lothian Birth Cohort, FHS: Framingham Heart Study, NAS: Normative Aging Study. 
Figure 1 Plot of predicted methylation age against chronological age and plot of 
Hannum versus Horvath predicted methylation age. LBC: Lothian Birth Cohort, NAS: 
Normative Aging Study, FHS: Framingham Heart Study. r = Pearson correlation coefficient. 
*To prevent the potential identification of individual participants, only FHS data points with 
chronological ages between 45 and 85, and NAS data points between ages 56 and 100 are 
displayed. 
Methylation age acceleration predicts mortality 
In the meta-analysed results across the four cohorts, a five year higher Hannum ∆age was 
associated with a 21% (95% CI [1.14, 1.29], P < 0.0001) greater mortality risk after 
adjustment for chronological age and sex (Figure 2). The corresponding increase in mortality 
risk for the Horvath ∆age was 11% (95% CI [1.05, 1.18], P = 0.0003). Kaplan-Meier survival 
curves for the Horvath and Hannum ∆age (split into highest versus lowest quartile, for 
descriptive purposes only) in these models are presented in Figure 3 for the LBC1921 
sample, which was the study with the greatest number of deaths. The plot illustrates the 
higher mortality rate for those with higher ∆age. 
Figure 2 Meta-analysis results of ∆age versus mortality. LBC: Lothian Birth Cohort, NAS: 
Normative Aging Study, FHS: Framingham Heart Study. HR: Hazard Ratio, CI: confidence 
interval, W: fixed effect weight. The basic adjusted models controlled for chronological age, 
sex (NAS had only male participants), and laboratory batch (FHS only). The fully adjusted 
models controlled for chronological age, sex, smoking, education, childhood IQ (LBC1921 
and LBC1936 only), social class (LBC1921 and LBC1936 only), APOE (LBC1921, 
LBC1936, and NAS only), cardiovascular disease, high blood pressure, and diabetes. 
Figure 3 Survival probability by quartiles of ∆age in LBC1921 adjusted for sex, and 
chronological age. LBC: Lothian Birth Cohort. 
Association between methylation age indicators and white blood cell counts 
It is well known that blood cell types have distinct methylation profiles [21,22]. A sensitivity 
analysis adjusting for measured white blood cell counts (basophils, eosinophils, monocytes, 
lymphocytes, and neutrophils) resulted in mostly minor differences to the results (Additional 
file 2). 
In addition to the five white blood cell types, we also examined the association between 
estimated naive T cell abundance and ∆age. However, to prevent spurious correlations 
between ∆age, which by definition correlates negatively with age, and cell counts, we used age 
acceleration defined as the residuals from a regression of predicted age on chronological age. 
There were stronger associations with these measures and the Hannum predictor (naive CD4+ 
T cells, average correlation r = −0.35, naive CD8+ T cells, average r = −0.34) compared to 
the Horvath predictor (r = −0.20, and −0.20, respectively). After adjustment for naive T cells, 
both predictors were still significantly associated with mortality. Naive T cell count was also 
associated with mortality in addition to the Hannum predictor (Additional file 3). 
Chronological age had a significant negative relationship with the abundance of naive T cells 
(on average r = −0.12 for CD8+ and r = −0.10 for CD4+ T cells, Additional file 3). 
The moderately strong correlation between naive T cell abundance and the Hannum predictor 
suggests that the latter keeps track of the age related decline of certain T cell populations. 
This makes sense in light of the facts that a) the Hannum predictor was constructed on the 
basis of DNA methylation data from whole blood and b) that naive T cells diminish with age 
due to age related thymic involution. In contrast to the Hannum predictor, the Horvath 
predictor exhibits a weaker relationship with naive T cell abundance, which probably reflects 
the fact that it was constructed on a range of different tissues and cell types. 
Adjusting for demographic variables and risk factors 
Sensitivity analyses were performed to control for potentially confounding variables: 
smoking, education, childhood IQ (LBC1921 and LBC1936 only), social class (LBC1921 
and LBC1936 only), APOE (LBC1921, LBC1936, and NAS only), cardiovascular disease, 
high blood pressure, and diabetes. When entered together in a fully adjusted model (Figure 2) 
the meta-analysed hazards ratio (HR) per 5 year increment was 1.16 (95% CI [1.08, 1.25], P 
= <0.0001) for the fully adjusted Hannum ∆age and 1.09 (95% CI [1.02, 1.15], P = 0.0069) for 
the fully adjusted Horvath ∆age. In the LBC datasets, which were the only datasets to contain 
information on all of the covariates, inclusion of the covariates one at a time made very little 
difference to basic, age- and sex-adjusted results (Additional file 4). 
Separate age-adjusted Cox models for men and women are presented in Additional file 5; 
there was no notable difference in the relation of ∆age to survival by sex. Sensitivity analyses 
that excluded deaths within the first two years of follow-up made negligible differences to the 
effect size and significance of the ∆age associations (Additional file 6). 
We tested the associations between ∆age and several key covariates (Additional file 7). With 
the exception of sex, where women had significantly lower ∆age estimates than men, there 
were no consistent associations with the covariates. There was some evidence for an 
association between the Hannum (but not Horvath) ∆age and childhood IQ and social class, 
although these covariates were assessed in only the two LBC cohorts. 
Heritability of methylation ∆age 
Using data from the BSGS cohort, the estimated heritability for the Horvath and Hannum ∆age 
was 0.43 (SE 0.07, P = 9x10−13) and 0.42 (SE 0.07, P = 4x10−10), respectively, indicating that 
approximately 40% of inter-individual differences in ∆age are due to genetic factors. The 
contribution to heritability broken down across relationship classes is given in Figure 4, and 
is consistent with an additive genetic model of inheritance. 
Figure 4 Heritability of methylation ∆age. (A) Intra-class correlation of Hannum and 
Horvath ∆age across relationship class (B) heritability of Hannum and Horvath ∆age in BSGS 
data. Both plots show estimates with standard errors. *Pseudo-independent pairs. r represents 
the degree of relatedness. 
Discussion 
The difference between DNA methylation predicted age and chronological age (∆age) using 
two sets of epigenetic markers [10,11] is a heritable trait that is associated with an increased 
risk of mortality in four independent cohorts of older individuals. This association is 
independent of life-course predictors of ageing and death such as possession of the e4 allele 
of APOE, education, childhood IQ, social class, diabetes, high blood pressure, and 
cardiovascular disease. Moreover, there was no clear association between these factors and 
∆age. 
A strength of our study is that we evaluate two distinct epigenetic biomarkers of ageing, ∆age, 
one from DNA methylation in whole blood, and one based on results across multiple tissues. 
The associations between ∆age and mortality were stronger for the blood-based predictor but 
the two measures became comparable after adjusting for naive CD8 T cell abundances 
(Additional file 3). It is well known that immunosenescence is accompanied by diminishing 
naive T cells due to thymic involution and that the ageing immune system is a predictor of 
human longevity [23,24]. While it is possible that the association between accelerated 
epigenetic age and all cause mortality is mediated by changes in blood cell composition, we 
think that this is unlikely for the following reasons. First, the Horvath measure only exhibited 
a weak relationship (average r = −0.20) with naive T cell abundance which reflects its 
definition and applicability to most tissues and cell types. Second, both measures remained 
significant predictors of mortality in multivariate regression models that adjusted for naive T 
cell abundances. 
Given the similarity of the findings for the two epigenetic biomarkers of ageing, it is a 
credible hypothesis that ∆age is an epigenetic biomarker of the pace of biological aging 
throughout life. 
Nearly all biological and lifestyle factors that we studied did not materially influence either 
the Hannum or Horvath ∆age across the four cohorts. Specifically, vascular insults, as 
measured by diabetes and hypertension, which are linked to cognitive decline, dementia, and 
death [25-27], were not associated with ∆age. There were sex differences, with men having 
higher ∆age than women, which is consistent with previous findings [10]. Childhood IQ and 
social class were modestly associated with ∆age in the two Lothian Birth Cohorts; an 
increased IQ in childhood and a less deprived social class were associated with lower ∆age in 
later life, although these were driven almost entirely by LBC1936. These correlated variables 
have been repeatedly associated with a range of health inequalities, including mortality [28], 
and it is possible that ∆age might offer insight into the mechanisms by which they are linked 
to health outcomes. 
Conclusions 
There is continued interest in identifying new risk factors, environmental, genetic, and 
epigenetic that can improve our ability to predict disease and mortality. Epidemiological 
studies have identified numerous measures from across the human life-course that are 
associated with an increased risk of mortality. These include health factors such as 
cardiovascular disease, diabetes and hypertension [27], genetic factors such as presence of the 
APOE e4 allele [29], lifestyle variables such as smoking [30] and education [31], behavioural 
traits such as cognitive ability [31,32], the personality trait of conscientiousness [33], and 
candidate biomarkers of age such as telomere length [34,35]. Here, we report on an 
epigenetic biomarker that is predictive of human mortality, after accounting for known risk 
factors. We found that two heritable DNA methylation-based measures of the difference 
between epigenetic age and chronological age are significant predictors of mortality in our 
meta-analysis of four independent cohorts of older people. Individual genetic or 
environmental exposures that drive the associations are not yet known, but they appear not to 
be clearly linked to classic life-course risk factors. The difference between DNA methylation 
age and chronological age predicts mortality risk over and above a combination of smoking, 
education, childhood IQ, social class, APOE genotype, cardiovascular disease, high blood 
pressure, and diabetes. It may therefore be possible to think of DNA methylation predicted 
age as an 'epigenetic clock' [11] that measures biological age and runs alongside, but not 
always in parallel with chronological age, and may inform life expectancy predictions. Our 
results imply that epigenetic marks, such as gene methylation, are like other complex traits: 
influenced by both genetic and environmental factors and associated with major health-
related outcomes. 
Materials and methods 
Cohort descriptions 
The Lothian Birth Cohort 1921 
Data were from the Lothian Birth Cohort 1921 (LBC1921), which is the basis of a 
longitudinal study of ageing [13,15]. Participants were born in 1921 and most completed a 
cognitive ability test at about age 11 years in the Scottish Mental Survey 1932 (SMS1932) 
[36]. The SMS1932 was administered nationwide to almost all 1921-born children who 
attended school in Scotland on June 1st 1932. The cognitive test was the Moray House Test 
No. 12, which provides a measure of general cognitive ability and has a scoring range 
between 0 and 76. The LBC1921 study attempted to follow up individuals who might have 
completed the SMS1932 and resided at about age 79 years in the Lothian region (Edinburgh 
and its surrounding areas) of Scotland; 550 people (n = 234, 43% men) were successfully 
traced and participated in the study from age 79 years. To date, there have been four 
additional follow-up waves at average ages of 83, 87, 90, and 92 years. The cohort has been 
deeply phenotyped during the later-life waves, including blood biomarkers, cognitive testing, 
and psycho-social, lifestyle, and health measures [13]. Genome wide single nucleotide 
polymorphisms and exome chip data are also available. DNA methylation measured in 
subjects at an average age of 79 (n = 514) was used for analyses in this report. 
Lothian Birth Cohort 1936 
The methylation mortality survival analysis was investigated in a second study, the Lothian 
Birth Cohort 1936 (LBC1936) [13,14]. All participants were born in 1936. Most had taken 
part in the Scottish Mental Survey 1947 at mean age 11 years as part of national testing of 
almost all children born in 1936 who attended Scottish schools on June 4th 1947 [37]. The 
cognitive test administered was the same Moray House Test No. 12 used in the SMS1932. A 
total of 1,091 participants (n = 548, 50% men) who were living in the Lothian area of 
Scotland were re-contacted in later life. Extensive phenotyping has also been carried out in 
this study, with data collection waves at three time points [13]. Genome wide single 
nucleotide polymorphisms and exome chip data are also available. DNA methylation was 
measured in 1,004 subjects at Wave 1 (mean age 70 years). To date, there have been two 
additional follow-up waves at average ages of 73, and 76. 
The Framingham Heart Study 
Framingham Heart Study (FHS) is a community based longitudinal study of participants 
living in and near Framingham, MA, at the start of the study in 1948 [16]. The Offspring 
cohort was comprised of the children and spouses of the original FHS participants, as 
described previously [17]. Briefly, enrollment for the Offspring cohort began in 1971 (n = 
5,124), and in-person evaluations occurred approximately every 4 to 8 years thereafter. The 
current analysis was limited to participants from the Offspring cohort who survived until the 
8th examination cycle (2005–2008) and consented to genetics research. DNA methylation 
data of peripheral blood samples collected at the 8th examination cycle were available in 
2,741 participants. 
The Normative Aging Study 
The US Department of Veterans Affairs (VA) Normative Aging Study (NAS) is an ongoing 
longitudinal cohort established in 1963, which included men who were 21–80 years of age 
and free of known chronic medical conditions at entry [18,19]. Participants were 
subsequently invited to medical examinations every three to five years. At each visit, 
participants provided information on medical history, lifestyle, and demographic factors, and 
underwent a physical examination and laboratory tests. DNA samples were collected from 
between 1999–2007 from the 675 active participants and used for DNA methylation analysis. 
We excluded 18 participants who were not of European descent or had missing information 
on race, leaving a total of 657 individuals. 
Brisbane Systems Genetics Study 
The Brisbane Systems Genetic Study (BSGS) [20] is a cohort comprising adolescent 
monozygotic (MZ) and dizygotic (DZ) twins, their siblings and their parents. They were 
originally recruited into an ongoing study of the genetic and environmental factors 
influencing cognition and pigmented nevi. DNA methylation was measured on 614 
individuals from 117 families of European descent. Families consist of adolescent 
monozygotic (MZ; n = 67 pairs) and dizygotic (DZ; n = 111 pairs) twins, their siblings (n = 
119), and their parents (n = 139). Children have a mean age of 14 years (range 9–23) and 
parents 47 years (range 33–75). 
Ethics 
LBC consent 
Following informed consent, venesected whole blood was collected for DNA extraction in 
both LBC1921 and LBC1936. Ethics permission for the LBC1921 was obtained from the 
Lothian Research Ethics Committee (Wave 1: LREC/1998/4/183). Ethics permission for the 
LBC1936 was obtained from the Multi-Centre Research Ethics Committee for Scotland 
(Wave 1: MREC/01/0/56), the Lothian Research Ethics Committee (Wave 1: 
LREC/2003/2/29). Written informed consent was obtained from all subjects. 
FHS consent 
All participants provided written informed consent at the time of each examination visit. The 
study protocol was approved by the Institutional Review Board at Boston University Medical 
Center (Boston, MA). 
NAS consent 
The NAS study was approved by the Institutional Review Boards (IRBs) of the participating 
institutions. Participants have provided written informed consent at each visit. 
BSGS consent 
The BSGS study was approved by the Queensland Institute for Medical Research Human 
Research Ethics Committee. All participants gave informed written consent. 
DNA Methylation measurement 
In all cohorts, bisulphite converted DNA samples were hybridised to the 12 sample Illumina 
HumanMethylation450BeadChips [38] using the Infinium HD Methylation protocol and 
Tecan robotics (Illumina, San Diego, CA, USA). 
LBC1921 and LBC1936 DNA methylation 
DNA was extracted from 514 whole blood samples in LBC1921 and from 1,004 samples in 
LBC1936. Samples were extracted at MRC Technology, Western General Hospital, 
Edinburgh (LBC1921) and the Wellcome Trust Clinical Research Facility (WTCRF), 
Western General Hospital, Edinburgh (LBC1936), using standard methods. Methylation 
typing of 485,512 probes was performed at the WTCRF. Raw intensity data were 
background-corrected and methylation beta-values generated using the R minfi package [39]. 
Quality control analysis was performed to remove probes with a low (<95%) detection rate at 
p < 0.01. Manual inspection of the array control probe signals was used to identify and 
remove low quality samples (e.g. samples with inadequate hybridisation, bisulfite conversion, 
nucleotide extension or staining signal). The Illumina-recommended threshold was used to 
eliminate samples with a low call rate (samples with <450,000 probes detected at p < 0.01). 
Since the LBC samples had previously been genotyped using the Illumina 610-Quadv1 
genotyping platform, genotypes derived from the 65 SNP control probes on the methylation 
array using the wateRmelon package [40] were compared to those obtained from the 
genotyping array to ensure sample integrity. Samples with a low match of genotypes with 
SNP control probes, which could indicate sample contamination or mix-up, were excluded (n 
= 9). Moreover, 8 subjects whose predicted sex, based on XY probes, did not match reported 
sex were also excluded. 
FHS DNA Methylation 
Peripheral blood samples were collected at the 8th examination samples (2005–2008). 
Genomic DNA was extracted from buffy coat using the Gentra Puregene DNA extraction kit 
(Qiagen) and bisulfite converted using EZ DNA Methylation kit (Zymo Research 
Corporation). DNA methylation quantification was conducted in two laboratory batches. 
Methylation beta values were generated using the Bioconductor minfi package with 
background correction. Sample exclusion criteria included poor SNP matching of control 
positions, missing rate >1%, outliers from multi-dimensional scaling (MDS), and sex 
mismatch. Probes were excluded if missing rate >20%. In total, 2,635 samples and 443,304 
CpG probes remained for analysis. 
NAS DNA Methylation 
DNA was extracted from buffy coat using the QIAamp DNA Blood Kit (QIAGEN, Valencia, 
CA). 500 ng of DNA was used to perform bisulfite conversion using the EZ-96 DNA 
Methylation Kit (Zymo Research, Orange, CA). To limit chip and plate effects, a two-stage 
age-stratified algorithm was used to randomise samples and ensure similar age distributions 
across chips and plates; we randomised 12 samples – which were sampled across all the age 
quartiles – to each chip, then chips were randomised to plates (each housing eight chips). 
Quality control analysis was performed to remove samples where >1% of probes had a 
detection p-value > 0.05. The remaining samples were preprocessed using the Illumina-type 
background correction without normalization as reimplemented in the Bioconductor minfi 
package, which was used to generate methylation beta values [39]. All 485,512 CpG and 
CpH probes were in the working set. 
BSGS DNA Methylation 
DNA was extracted from peripheral blood lymphocytes by the salt precipitation method [41] 
from samples that were time matched to sample collection of PAXgene tubes for gene 
expression studies in the Brisbane Systems Genetics Study [20]. Bisulphite converted DNA 
samples were hybridised to the 12 sample Illumina HumanMethylation450 BeadChips using 
the Infinium HD Methylation protocol and Tecan robotics (Illumina, San Diego, CA, USA). 
Samples were randomly placed with respect to the chip they were measured on and to the 
position on that chip in order to avoid any confounding with family. Box-plots of the red and 
green intensity levels and their ratio were used to ensure that no chip position was under- or 
over-exposed, with any outlying samples repeated. Similarly, the proportion of probes with 
detection p-value less than 0.01 was examined to confirm strong binding of the sample to the 
array. Raw intensity values were background corrected using the Genome Studio software 
performing normalization to internal controls and background subtraction. 
Mortality ascertainment 
LBC mortality ascertainment 
For both LBC1921 and LBC1936, mortality status was obtained via data linkage from the 
National Health Service Central Register, provided by the General Register Office for 
Scotland (now National Records of Scotland). Participant deaths and cause of death are 
routinely flagged to the research team on approximately a 12-weekly basis. 
FHS mortality ascertainment 
Deaths that occurred prior to January 1, 2013 were ascertained using multiple strategies, 
including routine contact with participants for health history updates, surveillance at the local 
hospital and in obituaries of the local newspaper, and queries to the National Death Index. 
We requested death certificates, hospital and nursing home records prior to death, and 
autopsy reports. When cause of death was undeterminable, the next of kin were interviewed. 
The date and cause of death were reviewed by an endpoint panel of 3 investigators. 
NAS mortality ascertainment 
Regular mailings to study participants have been used to maintain vital-status information, 
and official death certificates were obtained for decedents from the appropriate state health 
department. Death certificates were reviewed by a physician, and cause of death coded by an 
experienced research nurse using ICD-9. Both participant deaths and cause of death are 
routinely updated by the research team and last update available was December 31st, 2013. 
Covariate measurement 
LBC covariates 
Mortality-associated variables assessed in LBC1921 and LBC1936 were used as covariates in 
the statistical models: educational attainment, age-11 cognitive ability, APOE e4 status 
(carriers versus non-carriers), smoking status, and the presence or absence of diabetes, high 
blood pressure, or cardiovascular disease. Age-11 cognitive ability (age-11 IQ) was measured 
in 1932 for LBC1921 and in 1947 for LBC1936 using the Moray House Test Number 12, 
described above. All other variables were measured at the late-life baseline waves (age 79 for 
LBC1921 and age 70 for LBC1936). APOE was genotyped from venous blood using PCR 
amplification of a 227-bp fragment of the APOE gene, which contains the two single 
nucleotide polymorphisms that are used to define the e2, e3, and e4 alleles [42] in LBC1921, 
and by TaqMan technology (Applied Biosystems, Carlsbad, CA, USA) in LBC1936. Subjects 
were then categorised by the presence or absence of the e4 allele. Social class was based on 
the most prestigious occupation held by the participant prior to retirement. It was grouped 
into five categories in LBC1921 and six categories in LBC1936, where Class III was split 
into manual and non-manual professions [43,44]. It was treated as a continuous variable with 
lower values representing the more prestigious classes. The other variables were determined 
via self-report: number of years of education (measured as a continuous variable), diabetes 
(yes/no), high blood pressure (yes/no), cardiovascular disease (yes/no), and categorical 
smoking status (current/ex-smoker, never smoked). 
Given the known influence of blood cell count on methylation [21], we adjusted for five 
types of white blood cell count (basophils, monocytes, lymphocytes, eosinophils, and 
neutrophils) that were measured at on the same blood that was analysed for methylation. 
These data were collected and processed the same day; technical details are reported in 
McIllhagger et al. [45]. 
FHS covariates 
At the 8th in-person examination visit participants completed a questionnaire that inquired 
about their education, occupation, smoking status, and disease status. Highest levels of 
educational attainment was assessed by 8 categories—no schooling, grades 1–8, grades 9–11, 
completed high school or GED, some college but no degree, technical school certificate, 
associate degree, Bachelor’s degree, graduate or professional degree. Smoking status was 
dichotomized as current/past smokers and those who reported to never have smoked. 
Diabetes was defined as having fasting blood glucose ≥126 mg/dl or current treatment for 
diabetes. Hypertension was defined as having systolic blood pressure ≥140 mmHg, diastolic 
blood pressure ≥90 mmHg, or current treatment for hypertension. Cardiovascular disease was 
determined by a panel of 3 physicians, who reviewed participants' medical records, laboratory 
findings, and clinic exam notes. 
NAS covariates 
At each in-person examination visit, participants completed a questionnaire that enquired 
about their smoking status, education, diabetes (self-reported diagnosis and/or use of diabetes 
medications), and diagnosis of coronary heart disease (validated on medical records, ECG, 
and physician exams). High blood pressure was defined as antihypertensive medication use 
or SBP ≥ 140 mmHg or DBP ≥ 90 mmHg at study visit. APOE-e4 allele status was assessed 
through genotyping on a Sequenom MassArray MALDI-TOF mass spectrometer. 
Estimated naive T cell abundance 
In LBC1921, LBC1936, FHS, and NAS, we considered the abundance of defined different 
subtypes of T cells: Naïve T cells were defined as RA+ IL-7 Receptor + cells. Central 
Memory T cells = RA negative IL7 Receptor positive Effector memory = RA negative 
IL7Receptor negative. To estimate the naïve T cells in our cohort studies, we used a 
prediction method that was developed on an independent data set. The predictor of T cell 
counts (e.g., naïve CD4 T cell count) was found by applying a penalized regression model 
(elastic net) to regress T cell counts (dependent variable) on a subset of CpGs reported in 
Supplemental Table 3 from Zhang et al. [46]. By applying this resulting penalized regression 
model to our data, we arrived at predicted T cell counts. 
Data availability 
LBC methylation data have been submitted to the European Genome-phenome Archive under 
accession number EGAS00001000910; phenotypic data are available at dbGaP under the 
accession number phs000821.v1.p1. The FHS and NAS data are available at dbGaP under the 
accession numbers phs000724.v2.p9 phs000853.v1.p1, respectively. BSGS methylation data 
are available from the NCBI Gene Expression Omnibus under accession number GSE56105. 
Statistical analyses 
Two measures of DNA methylation age (mage) were calculated. The Horvath [11] mage uses 
353 probes common to the Illumina 27 K and 450 K Methylation arrays using data from a 
range of tissues and cell types. The Hannum [10] mage is based on 71 methylation probes 
from the Illumina 450 K Methylation array derived as the best predictors of age using data 
generated from whole blood. Of the Hannum age predictor probes, 70, 71, and 71 were 
included in the LBC, NAS, and FHS data, respectively. mage was calculated as the sum of the 
beta values multiplied by the reported effect sizes for the Hannum predictor. For the Horvath 
predictor, mage was determined in all cohorts using the online calculator 
(http://labs.genetics.ucla.edu/horvath/dnamage/). A third predictor, based on the three probes 
highlighted in the Weidner et al. paper [12], was also examined although, due to its poorer 
predictive accuracy, it was not included for the main analyses. To account for technical 
variability in the measurement of the methylation CpGs in the LBC studies, mage was adjusted 
for plate, array, position on the chip, and hybridisation date (all treated as fixed effect factors) 
using linear regression. In a sensitivity analysis, additional adjustments were made for white 
blood cell counts (the number of basophils, monocytes, lymphocytes, eosinophils, and 
neutrophils per volume of blood) or DNA methylation-estimated cell counts, as described 
elsewhere [21]. The residuals from these models were added to the mean predicted 
methylation age to give the new, adjusted measure of mage. The two methylation age 
predictors contained 6 overlapping probes. A methylation-based age acceleration index (∆age) 
was calculated for all subjects, defined as the adjusted methylation age in years minus 
chronological age at sample collection in years (∆age = mage – chronological age). 
Cox proportional hazards regression models were used to test the association between the 
Horvath and Hannum measures of ∆age and mortality, adjusting for age at sample collection, 
and sex. Cox models in FHS further adjusted for laboratory batch (fixed effect) and used a 
robust variance estimator to account for familial relatedness. Hazard ratios for ∆age were 
expressed per 5 years of methylation age acceleration. Schoenfeld residuals were examined to 
test the proportional hazards assumption. Sensitivity analyses, also using Cox proportional 
hazards regression, excluded deaths within the first 2 years of follow-up to eliminate the 
potential influences of (fatal) acute illness on the methylation measurements. Analyses to 
account for possible confounders/mediators included potential life-course predictors of 
mortality: age-11 IQ (LBC only), education in years, social class (LBC only), APOE e4 
carrier status (LBC and NAS), smoking status, and self-reported diabetes, high blood 
pressure, and cardiovascular disease. A fully adjusted model was tested, in which all 
variables were entered together. Chronological age- and sex-adjusted linear regression 
models were used to explore the relationship between ∆age and the additional covariates; e.g., 
does methylation age acceleration depend on smoking or diabetes? 
The results from the individual cohorts were meta-analysed using the 'meta' package in R 
[47]. The cohorts were weighted based on the standard errors of the log hazard ratios. There 
was no evidence of cohort heterogeneity in the primary Cox model analyses according to the 
DerSimonian-Laird estimator of between-study variance so fixed effects models were 
considered. 
All analyses were performed in the statistical software R [48] with the Cox models utilising 
the survival library [49]. 
Finally, we calculated the heritability of ∆age in the BSGS cohort. As mage was a better 
predictor of chronological age in the adult compared to adolescent samples, the difference 
between methylation age and chronological age was firstly standardised within generations 
(parents and offspring). Regression models were fitted to methylation age removing the 
effects of age and sex. Additionally, the regression on the adolescent samples included age2 
to account for the non-linearity between chronological and methylation age [11]. The 
residuals from these regressions were standardised to have a variance of 1 before combining 
the generations. See Additional file 8 for a graphical representation of the correction 
performed. 
For each probe, the Intra Class Correlation of ∆age for the various relative pairs was calculated 
using ANOVA as follows: 
ICC =
MSB − MSW
MSB +MSW   
where MSB is the Mean Square Between pairs and MSW is the Mean Square Within. The 
confidence intervals were based on the number of pseudo-independent relative pair for each 
relationship. 
The heritability for each probe was estimated by partitioning its variance into additive genetic 
(Va) and environmental (Ve) component by fitting a linear mixed model of the form 
eZay ++= µ   
where y is the vector of adjusted methylation age, a is the additive genetic effects and e is the 
unique environmental effects (residuals). The model was fitted using QTDT [50]. 
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